Europe represents the second-largest market in the Medical Oxygen Concentrator Market , valued at USD 1.08 billion in 2024 and holding a 30% global share. The region's growth is driven by an increasing incidence of chronic respiratory diseases, supportive regulatory frameworks, and a strong emphasis on home healthcare solutions. The European market is characterized by advanced healthcare infrastructure, high patient awareness, and a commitment to improving respiratory care outcomes.

The European Medicines Agency (EMA) has implemented guidelines that facilitate the approval of innovative medical devices, enhancing market accessibility and ensuring product safety. The Medical Device Regulation (MDR) has strengthened requirements for clinical evidence and post-market surveillance, building confidence among healthcare providers and patients. The European Centre for Disease Prevention and Control reports increasing adoption of advanced respiratory support technologies across healthcare systems, improving patient outcomes.

Germany is a key contributor, with a 29% share valued at USD 0.31 billion, driven by advanced healthcare infrastructure and a strong medical technology manufacturing sector. The country's aging population and high prevalence of respiratory diseases create sustained demand for oxygen therapy solutions. The United Kingdom holds a 21% share valued at USD 0.23 billion, supported by a rising elderly population and increasing respiratory disorder cases. The National Health Service's focus on cost-effective, home-based care drives adoption of portable and stationary oxygen concentrators.

The competitive landscape in Europe features a mix of established global players and emerging startups. Philips (NL) , Drive DeVilbiss Healthcare (GB) , and GCE Group (SE) are prominent players, focusing on technological advancements and patient-centric solutions. The region's emphasis on sustainability and energy efficiency is also driving innovation in oxygen concentrator design. As Europe's population ages and the burden of chronic respiratory diseases remains high, the market is expected to maintain steady expansion, driven by innovation, regulatory support, and a strong commitment to patient-centered care.